10
A small dose
Whitepaper launched to address $40bn clinical trials challenge
A
new whitepaper has been launched to help address clinical trial challenges around the globe. Released by Havas Lynx Group, the new whitepaper argues that a patient centric approach is needed if engagement is to approve within clinical trials. Havax Lynx Group has released its ‘Patient Centricity on Trial’ whitepaper in order to provoke conversation and offer potential solutions to a problem that is costing lives and the sector more than $40bn every year.
The whitepaper looks at new methods of recruitment for instance such as digital channels and step-by-step educational information in order to help patients navigate the application process of clinical trials. More so, Havas Lynx Group argue that more awareness is needed if patients are to recognise clinical trials as being potential treatment options. “Today, more than 40 million patients are needed in around 300,000 clinical trials worldwide every year,” explained Claire Knapp,
managing director of Havas Lynx, part of the Havas Lynx Group. “These are staggering numbers for the clinical trials arena to meet, especially when you consider that 85% of trials are failing to retain enough patients. “The challenges are mounting with exorbitant costs and a complex environment for clinical research, where the era of the blockbuster drug has made way for increasing niched drugs that cater to smaller, harder to find populations,” Knapp said.
CENTRAL PHARMA TO DIGITISE SUPPLY CHAIN THROUGH VERATRAK TEAM-UP U
K-based software provider Veratrak has announced it will work with Central Pharma (CPO) to help the company digitise its supply chain.
help them to connect with their network, digitise these manual processes and secure their supply chain operations moving forward.”
Jason Lacombe, CEO at Veratrak said: “We are really pleased to be welcoming Central Pharma and their extensive customer and partner network to our platform.
Veratrak’s platform leverages blockchain technology to store data as part of an immutable ledger, permitting secure data sharing across a company’s supply chain partners. It’s designed to provide companies with full transparency of their supply chains and to ensure secure and compliant critical document transfer. Alwyn Smit, managing director at Central Pharma added: “By
“At present, all document approval and onboarding processes at Central Pharma are running through email and internal working groups. By introducing our platform, we can
partnering with Veratrak we are taking the first step required to build a fully digital end-to-end supply chain network, that ensures data integrity and secure sharing of information between partners. “We chose Veratrak because its platform was designed with the industry in mind. Its solution not only gives us control over our supply chain but also has the potential to add value to our operations. By using a collaborative platform that facilitates efficient workflow, we will be able to reduce lead times by improving order management.”